Hyperinsulinism is the most common cause of persistent hypoglycemia in infants and children To date, mutations in five genes are known to encode proteins that cause congenital hyperinsulinism ...

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, March 07, 2025 (GLOBE NEWSWIRE) -- The "Congenital Hyperinsulinism Market" report has been added to ResearchAndMarkets.com's offering. The congenital ...

Dublin, March 07, 2025 (GLOBE NEWSWIRE) -- The "Congenital Hyperinsulinism Market" report has been added to ResearchAndMarkets.com's offering. The congenital hyperinsulinism market has demonstrated ...

Mr. Harris is an experienced board member and commercial leader with a proven track record in the industry. Mr. Harris has spearheaded global product launches, built and led high-performing commercial ...

Zealand Pharma has suffered another setback in its bid to bring glucagon receptor agonist dasiglucagon for ultra-rare disease congenital hyperinsulinism (CHI) to the US market. For the second time ...

In October 2024, it concluded its first successful clinical trial on patients with congenital hyperinsulinism. It also extended its Lifesaving Gene Therapy Program to older children with Duchenne ...

Rezolute is a late-stage clinical biotech focused on improving outcomes for individuals with hypoglycemia caused by ...